Royalty Pharma PLC (NAS:RPRX)
$ 28.09 0.12 (0.43%) Market Cap: 12.67 Bil Enterprise Value: 17.27 Bil PE Ratio: 15.87 PB Ratio: 1.95 GF Score: 79/100

PTC Therapeutics Inc To Monetize Portion of Risdiplam Royalty Stream For $650 Million From Royalty Pharma PLC Call Transcript

Jul 20, 2020 / 12:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the PTC To Monetize a Portion of Risdiplam Royalty Stream Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Alex Kane, Investor Relations. Thank you. Please go ahead, sir.

Alex Kane
PTC Therapeutics, Inc. - IR Officer

Good morning, and thank you for joining us today to discuss this morning's announcement on the agreement with Royalty Pharma to monetize a portion of the risdiplam royalty stream. A press release with details about this morning's announcement can be found in the Investors section of our corporate website at ptcbio.com.

Before we start, let me remind you that today's call will include forward-looking statements based on current expectations. Please take a moment to review the posted slide containing our forward-looking statements. Our actual results could materially differ from these forward-looking statements, and such

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot